Preclinical News and Research

RSS

microRNA 451 enhances treatment response in stomach cancer patients: Research

"The high presence of microRNA 451 enhances the response to treatment with chemo-radiotherapy and increases the survival of patients with stomach cancer", explained Dr. Jesús García-Foncillas, chief researcher of the Pharmacogenomics Laboratory at the Applied Medical Research Centre (CIMA) and Director of Oncology at the University Hospital of Navarra. This was one of the results presented at the IV Congress of the Spanish Society for Pharmacogenetics and Pharmacogenomic, recently held at CIMA.

15 Sep 2010

Elsevier launches new Pharmacokinetics Module of PharmaPendium

Elsevier today announces that it has significantly increased its service offering to pharmaceutical R&D professionals with the launch of a new Pharmacokinetics Module of PharmaPendium-, the online resource for authoritative drug development data.

15 Sep 2010

Atox Bio doses first subject in AB103 Phase 1 study for severe bacterial infections and sepsis

Atox Bio Inc. today announced that it successfully completed the dosing of the first subject in its phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.

15 Sep 2010

Apricus Biosciences announces reformulation of Rituxan enables rectal delivery of biologics

Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, today announced results from a pre-clinical pharmacokinetic study showing the ability of NexACT to enable rectal delivery of biologics, such as human antibodies.

15 Sep 2010

GenVec completes initial milestone in collaboration with Novartis

GenVec, Inc. today announced that it has achieved the first milestone in its collaboration with Novartis, related to the development of treatments for hearing loss and balance disorders. The milestone was triggered by the successful completion of certain preclinical development activities.

14 Sep 2010

Stemedica Cell Technologies completes master bank of mesenchymal bone marrow-derived stem cells

Stemedica Cell Technologies, Inc., a world leader in adult stem cell manufacturing and research, announced today that it has completed its proprietary master bank of mesenchymal bone marrow-derived stem cells.

14 Sep 2010

Genmab announces update in corporate strategy

Genmab A/S announced today an update to its corporate strategy. Today's strategy update represents a new beginning for Genmab where we acknowledge our successes and learn from our mistakes.

14 Sep 2010

VBL Therapeutics' VB-201 candidate delays onset of EAE, shows potential for MS, CNS treatment

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the publication of preclinical data in the Journal of Neuroimmunology finding that its lead development candidate VB-201 significantly delayed the onset and severity of experimental autoimmune encephalomyelitis (EAE) in mice, the commonly used Multiple sclerosis.

14 Sep 2010

Progenics Pharmaceuticals presents findings of humanized monoclonal antibodies against C. difficile bacterium

Progenics Pharmaceuticals, Inc. today presented preclinical findings for its humanized monoclonal antibodies against the disease-causing toxins produced by the bacterium Clostridium difficile.

14 Sep 2010

Cell-enriched primary renal cells improve survival and augment kidney function in CKD rodents

Tengion, Inc., a leader in regenerative medicine, announced today the publication of a key study in the American Journal of Physiology Renal Physiology by researchers at Tengion. In the study, rodents with chronic kidney disease (CKD) were treated with healthy kidney cells to catalyze the regeneration of functional kidney tissue and delay disease progression, as evidenced by extended survival, improved kidney filtration, and reduced severity of kidney tissue pathology.

14 Sep 2010

Genmab, Seattle Genetics enter ADC research collaboration agreement

Genmab A/S and Seattle Genetics, Inc. announced today that the companies have entered into an antibody-drug conjugate (ADC) research collaboration agreement.

14 Sep 2010

Rib-X Pharmaceuticals presents positive preclinical data for delafloxacin at ICAAC Conference

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced the presentation of positive preclinical data for delafloxacin in four poster sessions at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

14 Sep 2010

Neoprobe Corporation presents information on Lymphoseek at TERACHEM Symposium

Neoprobe Corporation a diversified developer of innovative oncology surgical and diagnostic products, today announced that Senior Vice President of Pharmaceutical Research and Clinical Development, Dr. Frederick O. Cope, presented information on the Company's lead pipeline initiative, Lymphoseek, at the International Symposium on Technetium and Other Radiometals in Chemistry and Medicine (TERACHEM), held September 8-11, 2010 in Bressanone (Bolzano), Italy.

14 Sep 2010

Excelimmune presents positive results for HRPA therapy against MRSA infections

Excelimmune, Inc. announced positive results from preclinical studies evaluating the efficacy of its human recombinant polyclonal antibody (HRPA) therapy against infections caused by methicillin-resistant Staphylococcus aureus (MRSA).

14 Sep 2010

OSUCCC-James researchers identify experimental agent that targets chronic lymphocytic leukemia

Researchers at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) have identified an experimental agent that targets chronic lymphocytic leukemia and perhaps other proliferative disorders of lymphocytes.

14 Sep 2010

New 'Therapeutic Hypothermia and Temperature Management' journal

Therapeutic Hypothermia and Temperature Management, a new quarterly peer-reviewed journal from Mary Ann Liebert, Inc., publishers, covers all aspects of hypothermia and temperature considerations relevant to this exciting field, including its application in cardiac arrest, spinal cord and traumatic brain injury, stroke, myocardial ischemia, neurogenic fever, emergency medicine, ICU management, anesthesiology, pediatrics, and much more.

14 Sep 2010

Arno Therapeutics closes private placement to advance cancer treatment

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced that it has closed a private placement of its securities resulting in gross proceeds to the company of over $15 million.

14 Sep 2010

Pharmacyclics reports $9.3 million increase in total revenue for 2010 fiscal year

Pharmacyclics, Inc. today reported financial results for its fiscal year and fourth quarter which ended June 30, 2010.

14 Sep 2010

Synta expands STA-9090 Phase 2 clinical trial in NSCLC

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it was expanding its Phase 2 clinical trial of STA-9090 in patients with Stage IIIB and Stage IV non-small cell lung cancer (NSCLC) from up to 69 patients to up to 146 patients based on encouraging activity observed in the first stage of the two stage clinical trial.

13 Sep 2010

Relypsa completes $70M Series B financing

Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced the completion of a Series B financing totaling $70 million. OrbiMed Advisors, LLC, led the financing with participation from existing Relypsa investors New Leaf Venture Partners, 5AM Ventures, Delphi Ventures, Sprout Group and Mediphase Venture Partners.

13 Sep 2010

Preclinical News and Research

microRNA 451 enhances treatment response in stomach cancer patients: Research

Elsevier launches new Pharmacokinetics Module of PharmaPendium

Atox Bio doses first subject in AB103 Phase 1 study for severe bacterial infections and sepsis

Apricus Biosciences announces reformulation of Rituxan enables rectal delivery of biologics

GenVec completes initial milestone in collaboration with Novartis

Stemedica Cell Technologies completes master bank of mesenchymal bone marrow-derived stem cells

Genmab announces update in corporate strategy

VBL Therapeutics' VB-201 candidate delays onset of EAE, shows potential for MS, CNS treatment

Progenics Pharmaceuticals presents findings of humanized monoclonal antibodies against C. difficile bacterium

Cell-enriched primary renal cells improve survival and augment kidney function in CKD rodents

Genmab, Seattle Genetics enter ADC research collaboration agreement

Rib-X Pharmaceuticals presents positive preclinical data for delafloxacin at ICAAC Conference

Neoprobe Corporation presents information on Lymphoseek at TERACHEM Symposium

Excelimmune presents positive results for HRPA therapy against MRSA infections

OSUCCC-James researchers identify experimental agent that targets chronic lymphocytic leukemia

New 'Therapeutic Hypothermia and Temperature Management' journal

Arno Therapeutics closes private placement to advance cancer treatment

Pharmacyclics reports $9.3 million increase in total revenue for 2010 fiscal year

Synta expands STA-9090 Phase 2 clinical trial in NSCLC

Relypsa completes $70M Series B financing

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News